LYS.PA
Lysogene S.A. [LYS.PA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
LYS.PA Stock Summary
In the News
LYS.PA Financial details
Company Rating
-
Market Cap
4.95M
Income
-5.95M
Revenue
10.93M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
22
Optionable
No
Shortable
Yes
Earnings
14 Oct 2022
P/E
-0.34
Forward P/E
-
PEG
-0.08
P/S
1.33
P/B
-1.08
P/C
-
P/FCF
-0.34
Quick Ratio
0.85
Current Ratio
1.21
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.46
EPS next Y
-
EPS next Q
-
EPS this Y
153.13%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-70%
ROE
-1151%
ROC
-2.52%
Gross Margin
49%
Oper. Margin
-356%
Profit Margin
-373%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.225-0.819
52W High
-
52W Low
-
RSI
-
Rel Volume
-
Avg Volume
-
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.908648
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
Company Profile
- Market Capitalization 4.95M
- Employee 22
- CEO Ms. Karen Pignet-Aiach MBA
- Headquarters Neuilly-sur-Seine,FR
- IPO Date 2017-02-08
-
Website
https://www.lysogene.com 
Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was incorporated in 2009 and is based in Neuilly-sur-Seine, France.
